50% OFF
MarketBeat All Access
Get 30 days free. Save 50% your first year.
  •  days
  •  Hours
  •  Minutes
  •  Seconds
×
S&P 500   3,693.23
DOW   29,590.41
QQQ   275.51
Get 1TB of Top-Rated Cloud Storage for Life for Just $112
The 3-Stock Retirement Blueprint (Ad)
Saudi Arabia's triumphant week reclaims the West's embrace
Poverty, inflation, fear: Egypt's economy pushed to brink
Why I Sued the Gov’t – And What I Recommend Now (Ad)
German leader continues Gulf tour with stops in UAE, Qatar
Labour conference starts with focus on 'immoral' tax cuts
Why I Sued the Gov’t – And What I Recommend Now (Ad)
Poverty and inflation: Egypt's economy hit by global turmoil
Kim Kardashian culls Dolce & Gabbana archives for Milan show
S&P 500   3,693.23
DOW   29,590.41
QQQ   275.51
Get 1TB of Top-Rated Cloud Storage for Life for Just $112
The 3-Stock Retirement Blueprint (Ad)
Saudi Arabia's triumphant week reclaims the West's embrace
Poverty, inflation, fear: Egypt's economy pushed to brink
Why I Sued the Gov’t – And What I Recommend Now (Ad)
German leader continues Gulf tour with stops in UAE, Qatar
Labour conference starts with focus on 'immoral' tax cuts
Why I Sued the Gov’t – And What I Recommend Now (Ad)
Poverty and inflation: Egypt's economy hit by global turmoil
Kim Kardashian culls Dolce & Gabbana archives for Milan show
S&P 500   3,693.23
DOW   29,590.41
QQQ   275.51
Get 1TB of Top-Rated Cloud Storage for Life for Just $112
The 3-Stock Retirement Blueprint (Ad)
Saudi Arabia's triumphant week reclaims the West's embrace
Poverty, inflation, fear: Egypt's economy pushed to brink
Why I Sued the Gov’t – And What I Recommend Now (Ad)
German leader continues Gulf tour with stops in UAE, Qatar
Labour conference starts with focus on 'immoral' tax cuts
Why I Sued the Gov’t – And What I Recommend Now (Ad)
Poverty and inflation: Egypt's economy hit by global turmoil
Kim Kardashian culls Dolce & Gabbana archives for Milan show
S&P 500   3,693.23
DOW   29,590.41
QQQ   275.51
Get 1TB of Top-Rated Cloud Storage for Life for Just $112
The 3-Stock Retirement Blueprint (Ad)
Saudi Arabia's triumphant week reclaims the West's embrace
Poverty, inflation, fear: Egypt's economy pushed to brink
Why I Sued the Gov’t – And What I Recommend Now (Ad)
German leader continues Gulf tour with stops in UAE, Qatar
Labour conference starts with focus on 'immoral' tax cuts
Why I Sued the Gov’t – And What I Recommend Now (Ad)
Poverty and inflation: Egypt's economy hit by global turmoil
Kim Kardashian culls Dolce & Gabbana archives for Milan show
NASDAQ:GERN

Geron - GERN Stock Forecast, Price & News

$2.30
-0.16 (-6.50%)
(As of 09/23/2022 12:00 AM ET)
Add
Compare
Today's Range
$2.24
$2.46
50-Day Range
$1.73
$2.94
52-Week Range
$0.99
$3.06
Volume
7.41 million shs
Average Volume
4.06 million shs
Market Capitalization
$868.99 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$4.50

Geron MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
95.7% Upside
$4.50 Price Target
Short Interest
Healthy
4.13% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-2.14
Upright™ Environmental Score
News Sentiment
0.58mentions of Geron in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
N/A

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.96 out of 5 stars

Medical Sector

728th out of 1,075 stocks

Pharmaceutical Preparations Industry

332nd out of 532 stocks

GERN stock logo

About Geron (NASDAQ:GERN) Stock

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in hematologic myeloid malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquartered in Foster City, California.

Receive GERN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Geron and its competitors with MarketBeat's FREE daily newsletter.

GERN Stock News Headlines

Geron (NASDAQ: GERN)
7 Top-Rated Biotech Stocks to Buy for Q4 - InvestorPlace
Geron (NASDAQ:GERN) Trading Up 1.8%
Geron - It's All About Imetelstat
Geron's Return On Capital Employed Insights
Geron - It's All About Imetelstat - RTTNews
Geron to Present at Upcoming Investor Conferences
Geron Commences Initial-Stage Rare Blood Cancer Combination Study
Geron (GERN) Q2 2022 Earnings Call Transcript
See More Headlines
Receive GERN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Geron and its competitors with MarketBeat's FREE daily newsletter.

GERN Company Calendar

Last Earnings
8/11/2022
Today
9/25/2022
Next Earnings (Estimated)
11/08/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:GERN
CUSIP
37416310
Employees
69
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$4.50
High Stock Price Forecast
$7.00
Low Stock Price Forecast
$3.00
Forecasted Upside/Downside
+95.7%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
4 Analysts

Profitability

Net Income
$-116,110,000.00
Net Margins
-8,693.61%
Pretax Margin
-8,693.61%

Debt

Sales & Book Value

Annual Sales
$1.39 million
Book Value
$0.39 per share

Miscellaneous

Free Float
355,150,000
Market Cap
$868.99 million
Optionable
Optionable
Beta
0.79

Key Executives

  • Dr. John A. Scarlett M.D. (Age 71)
    Chairman, Pres & CEO
    Comp: $1.26M
  • Ms. Olivia Kyusuk Bloom (Age 53)
    Exec. VP of Fin., CFO & Treasurer
    Comp: $743.27k
  • Dr. Andrew J. Grethlein (Age 58)
    Exec. VP & COO
    Comp: $767.28k
  • Ms. Melissa A. Kelly Behrs (Age 58)
    Exec. VP of Bus. Operations & Chief Alliance Officer
    Comp: $753.22k
  • Mr. Anil Kapur (Age 52)
    Exec. VP of Corp. Strategy & Chief Commercial Officer
    Comp: $654.89k
  • Ms. Aron Feingold
    VP of Investor Relations & Corp. Communications
  • Mr. Stephen N. Rosenfield J.D. (Age 72)
    Exec. VP, Chief Legal Officer & Corp. Sec.
  • Ms. Shannon Odam
    VP of HR
  • Mr. Edward E. Koval (Age 60)
    Exec. VP & Chief Bus. Officer
  • Dr. Faye Feller M.D. (Age 40)
    Exec. VP & Chief Medical Officer













GERN Stock - Frequently Asked Questions

Should I buy or sell Geron stock right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Geron in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" GERN shares.
View GERN analyst ratings
or view top-rated stocks.

What is Geron's stock price forecast for 2022?

4 brokerages have issued twelve-month target prices for Geron's stock. Their GERN share price forecasts range from $3.00 to $7.00. On average, they predict the company's stock price to reach $4.50 in the next year. This suggests a possible upside of 95.7% from the stock's current price.
View analysts price targets for GERN
or view top-rated stocks among Wall Street analysts.

How have GERN shares performed in 2022?

Geron's stock was trading at $1.22 on January 1st, 2022. Since then, GERN shares have increased by 88.5% and is now trading at $2.30.
View the best growth stocks for 2022 here
.

When is Geron's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 8th 2022.
View our GERN earnings forecast
.

How were Geron's earnings last quarter?

Geron Co. (NASDAQ:GERN) released its earnings results on Thursday, August, 11th. The biopharmaceutical company reported ($0.07) earnings per share for the quarter, beating analysts' consensus estimates of ($0.09) by $0.02. Geron had a negative trailing twelve-month return on equity of 90.38% and a negative net margin of 8,693.61%. During the same quarter last year, the company earned ($0.09) EPS.

What is John A. Scarlett's approval rating as Geron's CEO?

5 employees have rated Geron Chief Executive Officer John A. Scarlett on Glassdoor.com. John A. Scarlett has an approval rating of 82% among the company's employees.

What other stocks do shareholders of Geron own?
What is Geron's stock symbol?

Geron trades on the NASDAQ under the ticker symbol "GERN."

Who are Geron's major shareholders?

Geron's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Bioimpact Capital LLC (2.23%), Northern Trust Corp (0.96%), Millennium Management LLC (0.53%), Healthcare of Ontario Pension Plan Trust Fund (0.21%), Swiss National Bank (0.21%) and Goldman Sachs Group Inc. (0.20%).
View institutional ownership trends
.

How do I buy shares of Geron?

Shares of GERN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Geron's stock price today?

One share of GERN stock can currently be purchased for approximately $2.30.

How much money does Geron make?

Geron (NASDAQ:GERN) has a market capitalization of $868.99 million and generates $1.39 million in revenue each year. The biopharmaceutical company earns $-116,110,000.00 in net income (profit) each year or ($0.34) on an earnings per share basis.

How can I contact Geron?

Geron's mailing address is 919 EAST HILLSDALE BOULEVARD SUITE 250, FOSTER CITY CA, 94404. The official website for the company is www.geron.com. The biopharmaceutical company can be reached via phone at (650) 473-7700, via email at investor@geron.com, or via fax at 650-473-7750.

This page (NASDAQ:GERN) was last updated on 9/25/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.